The Journal of Cell Biology, Vol 119, 1137-1150, Copyright © 1992 by The Rockefeller University Press

ARTICLES

Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion

YA Ioannou, DF Bishop and RJ Desnick
Division of Medical and Molecular Genetics, Mount Sinai School of Medicine, New York 10029.

Human lysosomal alpha-galactosidase A (alpha-Gal A) was stably overexpressed in CHO cells and its biosynthesis and targeting were investigated. Clone AGA5.3-1000Mx, which was the highest enzyme overexpressor, produced intracellular alpha-Gal A levels of 20,900 U/mg (approximately 100 micrograms of enzyme/10(7) cells) and secreted approximately 13,000 U (or 75 micrograms/10(7) cells) per day. Ultrastructural examination of these cells revealed numerous 0.25-1.5 microns crystalline structures in dilated trans-Golgi network (TGN) and in lysosomes which stained with immunogold particles using affinity- purified anti-human alpha-Gal A antibodies. Pulse-chase studies revealed that approximately 65% of the total enzyme synthesized was secreted, while endogenous CHO lysosomal enzymes were not, indicating that the alpha-Gal A secretion was specific. The recombinant intracellular and secreted enzyme forms were normally processed and phosphorylated; the secreted enzyme had mannose-6-phosphate moieties and bound the immobilized 215-kD mannose-6-phosphate receptor (M6PR). Thus, the overexpressed enzyme's selective secretion did not result from oversaturation of the M6PR-mediated pathway or abnormal binding to the M6PR. Of note, the secreted alpha-Gal A was sulfated and the percent of enzyme sulfation decreased with increasing amplification, presumably due to the inaccessibility of the enzyme's tyrosine residues for the sulfotransferase in the TGN. Overexpression of human lysosomal alpha-N-acetylgalactosaminidase and acid sphingomyelinase in CHO cell lines also resulted in their respective selective secretion. In vitro studies revealed that purified secreted alpha-Gal A was precipitated as a function of enzyme concentration and pH, with 30% of the soluble enzyme being precipitated when 10 mg/ml of enzyme was incubated at pH 5.0. Thus, it is hypothesized that these overexpressed lysosomal enzymes are normally modified until they reach the TGN where the more acidic environment of this compartment causes the formation of soluble and particulate enzyme aggregates. A significant proportion of these enzyme aggregates are unable to bind the M6PR and are selectively secreted via the constitutive secretory pathway, while endogenous lysosomal enzymes bind the M6PRs and are transported to lysosomes.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Garzuly, F., Marodi, L., Erdos, M., Grubits, J., Varga, Z., Gelpi, E., Rohonyi, B., Mazlo, M., Molnar, A., Budka, H. (2005). Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the {alpha}-galactosidase A gene. Brain 128: 2078-2083 [Abstract] [Full Text]  
• He, X., Okino, N., Dhami, R., Dagan, A., Gatt, S., Schulze, H., Sandhoff, K., Schuchman, E. H. (2003). Purification and Characterization of Recombinant, Human Acid Ceramidase: CATALYTIC REACTIONS AND INTERACTIONS WITH ACID SPHINGOMYELINASE. J. Biol. Chem. 278: 32978-32986 [Abstract] [Full Text]  
• Lee, K., Jin, X., Zhang, K., Copertino, L., Andrews, L., Baker-Malcolm, J., Geagan, L., Qiu, H., Seiger, K., Barngrover, D., McPherson, J. M., Edmunds, T. (2003). A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13: 305-313 [Abstract] [Full Text]  
• Vogler, C., Galvin, N., Levy, B., Grubb, J., Jiang, J., Zhou, X. Y., Sly, W. S. (2003). Transgene produces massive overexpression of human beta -glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc. Natl. Acad. Sci. USA 100: 2669-2673 [Abstract] [Full Text]  
• Golabek, A. A., Kida, E., Walus, M., Wujek, P., Mehta, P., Wisniewski, K. E. (2003). Biosynthesis, Glycosylation, and Enzymatic Processing in Vivo of Human Tripeptidyl-peptidase I. J. Biol. Chem. 278: 7135-7145 [Abstract] [Full Text]  
• Chiba, Y., Sakuraba, H., Kotani, M., Kase, R., Kobayashi, K., Takeuchi, M., Ogasawara, S., Maruyama, Y., Nakajima, T., Takaoka, Y., Jigami, Y. (2002). Production in yeast of {alpha}-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology 12: 821-828 [Abstract] [Full Text]  
• Taylor, S. G., Osman, N., McKenzie, I. F.C., Sandrin, M. S. (2002). Reduction of {alpha}-Gal expression by relocalizing {alpha}-galactosidase to the trans-Golgi network and cell surface. Glycobiology 12: 729-739 [Abstract] [Full Text]  
• MIRANDA, S. R. P., HE, X., SIMONARO, C. M., GATT, S., DAGAN, A., DESNICK, R. J., SCHUCHMAN, E. H. (2000). Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14: 1988-1995 [Abstract] [Full Text]  
• Ohta, M., Ohnishi, T., Ioannou, Y. A., Hodgson, M. E., Matsuura, F., Desnick, R. J. (2000). Human {alpha}-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides. Glycobiology 10: 251-261 [Abstract] [Full Text]  
• Schissel, S. L., Keesler, G. A., Schuchman, E. H., Williams, K. J., Tabas, I. (1998). The Cellular Trafficking and Zinc Dependence of Secretory and Lysosomal Sphingomyelinase, Two Products of the Acid Sphingomyelinase Gene. J. Biol. Chem. 273: 18250-18259 [Abstract] [Full Text]  
• Salonen, T., Hellsten, E., Horelli-Kuitunen, N., Peltonen, L., Jalanko, A. (1998). Mouse Palmitoyl Protein Thioesterase: Gene Structure and Expression of cDNA. Genome Res 8: 724-730 [Abstract] [Full Text]  
• Marathe, S., Schissel, S. L., Yellin, M. J., Beatini, N., Mintzer, R., Williams, K. J., Tabas, I. (1998). Human Vascular Endothelial Cells Are a Rich and Regulatable Source of Secretory Sphingomyelinase. IMPLICATIONS FOR EARLY ATHEROGENESIS AND CERAMIDE-MEDIATED CELL SIGNALING. J. Biol. Chem. 273: 4081-4088 [Abstract] [Full Text]  
• Osman, N., McKenzie, I. F. C., Ostenried, K., Ioannou, Y. A., Desnick, R. J., Sandrin, M. S. (1997). Combined transgenic expression of alpha -galactosidase and alpha 1,2-fucosyltransferase leads to optimal reduction in the major xenoepitope Galalpha (1,3)Gal. Proc. Natl. Acad. Sci. USA 94: 14677-14682 [Abstract] [Full Text]  
• Zhao, K.-W., Faull, K. F., Kakkis, E. D., Neufeld, E. F. (1997). Carbohydrate Structures of Recombinant Human alpha -L-Iduronidase Secreted by Chinese Hamster Ovary Cells. J. Biol. Chem. 272: 22758-22765 [Abstract] [Full Text]  
• Bonten, E, van der Spoel, A, Fornerod, M, Grosveld, G, d'Azzo, A (1996). Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis.. Genes Dev. 10: 3156-3169 [Abstract]  
• Schissel, S. L., Schuchman, E. H., Williams, K. J., Tabas, I. (1996). Zn2+-stimulated Sphingomyelinase Is Secreted by Many Cell Types and Is a Product of the Acid Sphingomyelinase Gene. J. Biol. Chem. 271: 18431-18436 [Abstract] [Full Text]  
• Zhou, X Y, Morreau, H, Rottier, R, Davis, D, Bonten, E, Gillemans, N, Wenger, D, Grosveld, F G, Doherty, P, Suzuki, K (1995). Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells.. Genes Dev. 9: 2623-2634 [Abstract]  

Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents